Our top pick for
Cellectis S.A is a biotechnology business based in the US. Cellectis S-A shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis S-A employs 272 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.83|
|52-week range||$9.10 - $34.71|
|50-day moving average||$13.04|
|200-day moving average||$15.03|
|Wall St. target price||$26.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.78|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-07)||N/A|
|1 month (2021-09-17)||-24.95%|
|3 months (2021-07-16)||-23.46%|
|6 months (2021-04-16)||-44.18%|
|1 year (2020-10-16)||-44.97%|
|2 years (2019-10-18)||6.70%|
|3 years (2018-10-18)||26.97|
|5 years (2016-10-18)||19.55|
|Revenue TTM||$70.1 million|
|Gross profit TTM||$46.2 million|
|Return on assets TTM||-16.46%|
|Return on equity TTM||-41.75%|
|Market capitalisation||$493.8 million|
TTM: trailing 12 months
There are currently 1.3 million Cellectis S-A shares held short by investors – that's known as Cellectis S-A's "short interest". This figure is 1.6% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Cellectis S-A shares can be evaluated.
Cellectis S-A's "short interest ratio" (SIR) is the quantity of Cellectis S-A shares currently shorted divided by the average quantity of Cellectis S-A shares traded daily (recently around 107925.19413287). Cellectis S-A's SIR currently stands at 11.59. In other words for every 100,000 Cellectis S-A shares traded daily on the market, roughly 11590 shares are currently held short.
However Cellectis S-A's short interest can also be evaluated against the total number of Cellectis S-A shares, or, against the total number of tradable Cellectis S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectis S-A's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cellectis S-A shares in existence, roughly 30 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable Cellectis S-A shares, roughly 41 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cellectis S-A.
Find out more about how you can short Cellectis S-A stock.
We're not expecting Cellectis S-A to pay a dividend over the next 12 months.
Over the last 12 months, Cellectis S-A's shares have ranged in value from as little as $9.1 up to $34.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis S-A's is 2.2206. This would suggest that Cellectis S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.